Biofrontera AG (BFRA): Price and Financial Metrics

Biofrontera AG (BFRA)

Today's Latest Price: $7.81 USD

0.07 (-0.89%)

Updated Sep 25 4:00pm

Add BFRA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

BFRA Stock Summary

  • With a one year PEG ratio of 0.16, Biofrontera AG is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 3.89% of US stocks.
  • Of note is the ratio of Biofrontera AG's sales and general administrative expense to its total operating expenses; 98.57% of US stocks have a lower such ratio.
  • Revenue growth over the past 12 months for Biofrontera AG comes in at 130.84%, a number that bests 95.78% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Biofrontera AG, a group of peers worth examining would be UUU, TGEN, MGIC, CYAN, and IKNX.
  • BFRA's SEC filings can be seen here. And to visit Biofrontera AG's official web site, go to
BFRA Daily Price Range
BFRA 52-Week Price Range

BFRA Stock Price Chart Technical Analysis Charts

BFRA Price/Volume Stats

Current price $7.81 52-week high $55.00
Prev. close $7.88 52-week low $5.27
Day low $7.80 Volume 53,961
Day high $8.28 Avg. volume 435,064
50-day MA $10.18 Dividend yield N/A
200-day MA $11.22 Market Cap 175.14M

Biofrontera AG (BFRA) Company Bio

Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin. Biofrontera AG was founded in 1997 and is based in Leverkusen, Germany.

BFRA Latest News Stream

Event/Time News Detail
Loading, please wait...

BFRA Latest Social Stream

Loading social stream, please wait...

View Full BFRA Social Stream

Latest BFRA News From Around the Web

Below are the latest news stories about Biofrontera AG that investors may wish to consider to help them evaluate BFRA as an investment opportunity.

Biofrontera AG: German Federal Supreme Court overturns ruling of the Cologne Higher Regional Court

Leverkusen, Germany, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that in ruling on September 22, 2020, the German Federal Supreme Court overturned a decision by the Cologne Higher Regional Court dated November 15, 2018, which was directed against the Company. The overturned ruling of the Cologne Higher Regional Court concerned an action for rescission and annulment brought by the shareholder Deutsche Balaton AG against certain resolutions of the Annual General Meeting held on May 24, 2017. The matter has now been referred back to the Cologne Higher Regional Court for retrial and decision. The reasons for the ruling of the Federal Supreme Court are currently not avai...

Yahoo | September 22, 2020

Biofrontera AG plans mediation to resolve (legal) disputes

Leverkusen, Germany, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-Group”), an international biopharmaceutical company, today has reached a mutual agreement with Mr. Wilhelm K.T. Zours and Deutsche Balaton AG on the key elements of a mediation agreement. The completion of the mediation agreement is expected today. Within the framework of the mediation process, which is to commence shortly, an experienced and renowned mediator will be called in to find solutions for the settlement of disputes as well as disagreements on personnel and strategic corporate matters. Mr. Zours is chairman of the supervisory board and majority shareholder of Deutsche Balaton AG and is as such an indirect major shareholder of ...

Yahoo | September 11, 2020

Biofrontera AG to participate in two upcoming conferences

Leverkusen, Germany, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be participating virtually in two upcoming conferences. On September 17, 2020, members of Biofrontera's management team will attend the 2020 Lake Street Capital Markets Best Ideas Growth (BIG4) Conference and will be available for virtual one-on-one meetings with registered investors.On September 25, 2020, the management team will participate virtually in the Baader Investment Conference 2020. Following the company presentation, one-on-one meetings with institutional investors will take place.About the B.I.G. Conference: Lake Street will host its fourth annual B.I.G. (Best Ideas Growth) Investor Confe...

Yahoo | September 9, 2020

Biofrontera AG (BFRA) CEO Hermann Lübbert on Q2 2020 Results - Earnings Call Transcript

Biofrontera AG (BFRA) Q2 2020 Earnings Conference Call August 27, 2020 08:00 AM ET Company Participants Pamela Keck - Head, Investor Relations Hermann Lübbert - Chief Executive Officer Thomas Schaffer - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Bruce Jackson - The Benchmark Company...

SA Transcripts on Seeking Alpha | August 27, 2020

Biofrontera AG (BFRA) Q2 2020 Earnings Call Transcript

May I now hand you over to Pamela Keck, Head of Investor Relations, who will lead you for this conference. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business.

Yahoo | August 27, 2020

Read More 'BFRA' Stories Here

BFRA Price Returns

1-mo -24.54%
3-mo 17.27%
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
2019 0.00%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7185 seconds.